East Texas veterans facing vision challenges will receive AI-powered Ray-Ban glasses through a collaborative event on Aug. 20 ...

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on ...

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline ...

Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target ...

South Africa can reduce queues and administrative costs without losing an important opportunity to identify changes in ...

Florida Retina Specialists is expanding treatment options for patients with dry age-related macular degeneration by offering ...

Background Intraorbital space-occupying lesions impair visual function, yet whether this stems primarily from optic nerve ...

Tablet-based testing using the Angular Indication Measurement visual acuity test may support amblyopia management in children. A self-administered near visual acuity (VA) test using the Angular ...

ClearValue integrates Restb.ai’s AI-powered Complexity Assessment into Acuity to help lenders and AMCs identify complex ...

Ocular’s AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026. FDA Type C Meeting Minutes Formalize SOL-1 Trial ...

Jordana Fein, MD, MS, presented 64-week QUASAR data showing aflibercept 8 mg sustained visual acuity gains with up to 3 fewer injections than aflibercept 2 mg in macular edema following RVO.

Real-world Spectrum data show aflibercept 8 mg boosts early vision and retinal anatomy in wet AMD, including switch patients. Welcome back to another Ophthalmology Times Europe Rapid Readout. In this ...